亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南惠誠醫藥科技有限公司  

生產和銷售各類原料藥及其中間體,如:奧利司他、新利司他、利拉列汀、曲格列汀琥珀酸鹽、苯甲酸阿格列汀、卡格列凈半水合物、磷酸奧司他韋、瑞舒伐他汀鈣及其中間體、磷酸肌酸二鈉鹽、阿地溴銨、噻托溴銨一水合物、依替唑侖、丙戊酸鈉、美沙拉嗪、腎上腺素系列等。

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:趙攀峰
  • 電話:0531-68659623
  • 郵件:sales@hc-pharm.com
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 地西他濱
地西他濱
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 惠誠
過期 長期有效
更新 2017-07-19 10:00
 
詳細信息

中文名稱: 地西他濱

中文同義詞: 地西他濱;脫氧氮雜胞苷;5-氮雜-2'-脫氧胞苷;5-氮雜胞嘧啶脫氧胞苷;5-氮雜-2'-脫氧胞嘧啶核苷;2'-脫氧-5-氮雜胞啶;地西他濱/ 5-氮雜-2'-脫氧胞嘧啶核苷;地西他濱(99%,99.9%)

英文名稱: Decitabine

英文同義詞: 5-Aza-2'-deoxycytidine;4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-on;4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-one;5-azadeoxycytidine;5-triazin-2(1h)-one,4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-3;2'-DEOXY-5-AZACYTIDINE;4-AMINO-1-(2-DEOXY-BETA-D-RIBOFURANOSYL)-1,3,5-TRIAZIN-2(1H)-ONE;5-AZA-2'-DEOXYCYTIDINE;5-AZA-CDR

CAS: 2353-33-5

分子式: C8H12N4O4

分子量: 228.21

EINECS: 219-089-4

相關類別: 13-脫氧核糖及其衍生物;API;原料藥;bases & Related Reagents;Nucleotides;analog of cytosine;核苷類;科研試劑;化學試劑;Intermediates & Fine Chemicals;Pharmaceuticals;Epigenetics;Inhibitor;生化試劑;Deoxycytidine;Anti-cancer&immunity;核苷,核苷酸,寡核苷酸

溶解度  acetic acid/water (1:1): 50 mg/mL

穩定性 Stable. May be light or air sensitive. In*patible with strong oxidizing agents.

: 抗癌類藥物

©2025 濟南惠誠醫藥科技有限公司 版權所有   技術支持:化工網   訪問量:11462  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |